U.S. Stock Market Midday Update: 180 Life Sciences down 30.16%

U.S. Stock Market Midday Update 180 Life Sciences, down 30.16%, with a 5-day increase of 118.13%. Based on recent key news: On August 14, 180 Life Sciences announced a sales agreement to potentially issue and sell up to $500 million in common stock, leading to significant stock price fluctuations. On August 12, the company completed a $156 million private placement of convertible bonds to purchase Ethereum, resulting in a 54% increase in stock price. On August 12, billionaire Peter Thiel disclosed a 7.5% stake in the company, causing the stock price to rise over 11% in a single day. Stocks with High Trading Volume in the Industry CRISPR Therapeutics, up 1.26%, with a trading volume of $50.07 million. Based on recent key news: On August 11, security issues at PayPal raised market concerns, leading investors to doubt the company's future development, affecting the performance of related tech stocks. On August 13, Goldman Sachs raised the target price for Domino's Pizza Group to $26 per share, boosting market confidence in the consumer goods sector. On August 5, Domino's Pizza released its mid-2025 performance report, showing a 1.3% year-on-year increase in total sales, but rising raw material costs compressed profit margins, impacting overall market sentiment. Forte Pharmaceuticals, down 1.63%, with increased trading volume. Based on recent key news: On August 13, Forte Pharmaceuticals announced its Q2 2025 results, reporting a net profit of $1.033 billion, turning a profit, but the stock price did not respond positively and instead fell. On August 12, market analysis showed that 59% of options trading for Forte Pharmaceuticals was bearish, leading to pessimistic market sentiment and pressure on the stock price. On August 12, analysts downgraded the price expectations for Forte Pharmaceuticals; although the target price remains above the current price, it negatively impacted the stock price. Gilead Sciences, down 0.87%, with increased trading volume. Based on recent key news: On August 13, Gilead Sciences reported quarterly revenue of $7.082 billion, exceeding analyst expectations, but operating profit declined, leading to stock price volatility. On August 11, Goldman Sachs raised the target price for Gilead Sciences to $105, maintaining a "Neutral" rating, with a muted market response. On August 11, Gilead Sciences announced a $6 billion stock repurchase plan, providing short-term support for the stock price. Stocks with High Market Capitalization in the Industry AbbVie, up 0.15%, with increased trading volume. Based on recent key news: On August 13, AbbVie reported Q2 results, with revenue increasing by 6.6% year-on-year, exceeding market expectations, and adjusted earnings per share also above expectations, driving the stock price up On August 12, AbbVie announced an investment of $195 million to expand the manufacturing of active pharmaceutical ingredients in the United States, enhancing market confidence. On August 13, AbbVie received its first coverage from Piper Sandler with an overweight rating and a target price of $231, further supporting the stock price